IS6 was mainly distinguished by an enrichment of mutations in GATA3, which disrupts epithelial-to-mesenchymal transition (EMT) and inhibits the tumor-initiating ability of luminal progenitor cells and metastasis in breast cancer (44). This evidence concerns the gene GATA3 and breast cancer.